/NPCE

Neuropace Inc

NPCE

$14.04USD↑+1.23%+0.17 today

MARKET CAP

481.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$14 – $14

52W RANGE

$9

$20

AI Summary

Stalk

StalkMedium

NPCE remains in a Stage 2 advancing uptrend supported by rising EMAs, but the active Blow-Off Top pattern signals a climax of buying pressure and waning momentum. Short-term price is pulling back into the rising 9/21 EMA support zone on early RSI rollover, making immediate entry unfavorable. We will wait for a cleaner pullback into these dynamic support levels before engaging bullishly.

↑Q2 2026 revenue grew 17% YoY to $22.8M, driven by 21.3% RNS system sales growth
↑Raised full-year revenue guidance to $99.5–101.5M, signaling management confidence
↓Q2 2026 net loss was $6.2M, reflecting persistent cash burn

Full analysis →

Buying

5

institutions

Selling

4

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	2.48 M	39.37 M	+131.27 K	+27.6%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	173.31 K	2.86 M	+32.17 K	+58.1%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	128.80 K	2.05 M	+41.52 K	+78.3%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	111.70 K	1.77 M	+-62.61 K	-22.6%	0.00%
MG Man Group Plc Q2 2026	BUY	84.07 K	1.34 M	+40.18 K	+131.4%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	35.92 K	570.77 K	+7.92 K	+55.0%	0.00%
MM Millennium Management LLC Q2 2026	SELL	30.62 K	486.54 K	+-10.00 K	-8.9%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	SELL	0.00	0.00	+-152.03 K	-100.0%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	0.00	0.00	+-23.35 K	-100.0%	0.00%